By Dr Frank Po-Yen Lin

Preprints

Walpole I; Zaman FY; Zhao P; Marshall VM; Lin F; Thomas DM; Shackleton M; Antolin AA; Ameratunga M, 2023, Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases, http://dx.doi.org/10.1101/2023.07.01.547311

Thavaneswaran S; Lin F; Kansara M; Grady J; Espinoza D; Joshua A; Grimison P; Craft P; Cosman R; Lee C; Harwood K; Chinchen S; Corpuz T; Ballinger M; Sebastian L; Simes J; Thomas D, 2022, A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers, http://dx.doi.org/10.1101/2022.06.30.22277092

Thavaneswaran S; Sebastian L; Kansara M; Ballinger M; Espinoza D; Lin F; Lee C; Sjoquist K; Grady J; Cowley M; Joshua A; Qiu M; Oakes S; Simes J; Thomas D, 2021, A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program, http://dx.doi.org/10.21203/rs.3.rs-254137/v1

Lin FPY, 2020, Design and implementation of an intelligent framework for supporting evidence-based treatment recommendations in precision oncology, http://dx.doi.org/10.1101/2020.11.15.383448

Lin FPY; Salih OSM; Scott N; Jameson MB; Epstein RJ, 2020, Repurposing digitised clinical narratives to discover prognostic factors and predict survival in patients with advanced cancer, http://dx.doi.org/10.1101/2020.10.28.20214627

Lin F; Thavaneswaran S; Grady J; Ballinger M; Kansara M; Oakes S; Desai J; Lee CK; Simes J; Thomas D, 2020, Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology, http://dx.doi.org/10.1101/2020.12.18.20248521

Back to profile page